Sareum Holdings PLC
12 January 2007
For immediate release 12 January 2007
SAREUM HOLDINGS PLC
("Sareum" or the "Company")
Notice of Interim Results and R&D Update
Sareum Holdings plc (AIM: SAR), the specialist structure-based drug discovery
business, will be announcing its interim results for the six months ended 31
December 2006 on Tuesday 6 February 2007.
An analyst presentation will take place on the day at 10:00am at Buchanan
Communications, 45 Moorfields, London EC2Y 9AE.
In addition, on the same day, Sareum will be providing a research and
development update for analysts at 10.30am also at the offices of Buchanan
Communications.
The R&D update will include the following presentations:
What big pharma needs from biotech
Professor David Tapolczay, Vice President,
Technology Development, GlaxoSmithKline
Levering biotech collaborations to attract big pharma licencing deals
Dr Stephen Mayhew, Business Manager, Cancer Research Technology
Sareum's in-house pipeline and licencing strategy
Dr John Reader, Founder and VP Chemistry, Sareum
Copies of all the presentations will be available from 9.30am on 6 February 2007
from www.sareum.co.uk.
For further information please contact:
Buchanan Communications 020 7466 5000
Tim Anderson, Mary-Jane Johnson, Simon Potter
About Sareum Holdings plc
Sareum Holdings plc is a structure-based drug discovery business headquartered
in Cambridge, UK. The Company was formed in August 2003 to discover new drugs
for the treatment of cancer. Sareum's unique approach aims to halve the time it
takes to discover new drug candidates.
A structure-based approach to drug discovery relies on knowledge of the
three-dimensional structure of the proteins that cause disease. Once the
structure is known, potential drugs are designed to 'lock-in' to the protein
with the aim of reversing or arresting a disease's progression. Knowledge of
the structure of the potential drugs and how they 'lock-in' to their target
protein assists greatly in the development of high-quality drug candidates.
Determining structure is a complex task and requires leading-edge equipment and
experienced staff. Sareum's approach to structure determination utilises its
proprietary protein expression platform in order to produce multiple recombinant
proteins that accelerate structure determination using x-ray crystallography.
Once the structure is determined, the Company's innovative fragment screening
platform is used to identify novel chemical templates designed to interact with
the target protein. Sareum then uses its high-throughput medicinal chemistry
platform to rapidly optimise these molecules and develop the most promising into
potential drug candidates.
Sareum aims to successfully deliver drug candidates for licensing to larger
pharmaceutical companies at the pre-clinical or early clinical trials stage.
This is funded by provision of its specialist drug discovery capabilities to
partners in the pharmaceutical and biotechnology industries.
Sareum joined the AIM market of the London Stock Exchange in October 2004 and
trades under the symbol SAR. For further information, please visit
www.sareum.co.uk
This information is provided by RNS
The company news service from the London Stock Exchange